Drug General Information (ID: DDIL5N6SC0)
Drug Name			Fingolimod		Drug Info		Sacituzumab govitecan		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Selective Immunosuppressants				Antineoplastics
Structure

Mechanism of Fingolimod-Sacituzumab govitecan Interaction (Severity Level: Major)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Fingolimod				Sacituzumab govitecan
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Fingolimod and Sacituzumab govitecan

Recommended Action
Management		The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.

References
1	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.